Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Director Sells $190,838.78 in Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating) Director Sangeeta N. Bhatia sold 737 shares of the company’s stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $258.94, for a total value of $190,838.78. Following the transaction, the director now owns 5,903 shares of the company’s stock, valued at $1,528,522.82. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Shares of NASDAQ VRTX opened at $273.70 on Thursday. Vertex Pharmaceuticals Incorporated has a 12 month low of $176.36 and a 12 month high of $292.75. The company has a market cap of $69.94 billion, a price-to-earnings ratio of 30.31, a P/E/G ratio of 1.87 and a beta of 0.55. The company has a quick ratio of 4.30, a current ratio of 4.46 and a debt-to-equity ratio of 0.05. The business has a fifty day simple moving average of $259.65 and a 200-day simple moving average of $228.62.

A number of brokerages recently commented on VRTX. Piper Sandler upped their price objective on Vertex Pharmaceuticals from $245.00 to $249.00 and gave the stock a “neutral” rating in a research note on Thursday, April 21st. Wolfe Research increased their price target on Vertex Pharmaceuticals from $271.00 to $282.00 and gave the stock an “outperform” rating in a research note on Thursday, January 27th. HC Wainwright reissued a “buy” rating and issued a $275.00 price target on shares of Vertex Pharmaceuticals in a research note on Wednesday, March 23rd. Wells Fargo & Company increased their price target on Vertex Pharmaceuticals from $270.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 5th. Finally, UBS Group increased their price target on Vertex Pharmaceuticals from $258.00 to $325.00 in a research note on Wednesday, April 13th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $273.43.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Concord Wealth Partners lifted its holdings in shares of Vertex Pharmaceuticals by 750.0% during the fourth quarter. Concord Wealth Partners now owns 119 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 105 shares during the last quarter. First PREMIER Bank purchased a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at $27,000. Hudock Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 156.3% during the third quarter. Hudock Inc. now owns 164 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 100 shares during the last quarter. Moors & Cabot Inc. acquired a new position in Vertex Pharmaceuticals during the third quarter valued at $29,000. Finally, JJJ Advisors Inc. raised its position in Vertex Pharmaceuticals by 101.5% during the fourth quarter. JJJ Advisors Inc. now owns 133 shares of the pharmaceutical company’s stock valued at $29,000 after buying an additional 67 shares during the period. 89.84% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Company Profile (Get Rating)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

See Also

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.